Blood, kidney and liver donation are widely known, but medical science has introduced another unusual form of donation: stool donation. The treatment is called Faecal Microbiota Transplantation (FMT). It involves transferring beneficial bacteria from a healthy donor’s stool into a patient's gut to restore the balance of microorganisms.
Who Needs This Treatment?
FMT is mainly used for patients suffering from repeated infections caused by Clostridioides difficile (C. difficile). The infection can cause severe diarrhoea and other digestive problems. In some cases, antibiotics fail to prevent it from returning. FMT can help restore healthy gut bacteria and reduce the risk of another infection.
Who Are ‘Super Poopers’?
Not everyone can donate stool. Donors must undergo detailed medical checks, including blood and stool tests. Some people have particularly beneficial and diverse gut bacteria that may help patients recover more effectively. These donors are popularly called ‘super poopers’. Their stool can be especially valuable for medical treatment.
How Does Stool Donation Work?
The human gut contains millions of microorganisms that support digestion and overall health. Antibiotics and certain illnesses can disturb this balance, allowing harmful bacteria to multiply. FMT introduces beneficial microorganisms from a healthy donor. Depending on the treatment, it can be delivered through colonoscopy or specially prepared capsules.
Strict Screening for Donors
Donors are checked for infections, medical conditions, medication use, diet and lifestyle habits. Their travel history may also be reviewed to identify possible exposure to harmful infections. According to experts cited in the report, only around 3% of people pass the initial screening in some programmes. In Toronto, one expert reported an initial selection rate of just 1.6%, with only 0.6% qualifying as regular donors. Some stool banks in the US pay donors around $25 to $100 per donation.
Can Stool Become Medicine?
Researchers are studying how beneficial gut bacteria can be used in future treatments. The US FDA has approved REBYOTA, a stool-derived rectal product, and VOWST, an oral capsule containing bacterial spores, to prevent recurrent C. difficile infection. Scientists are also studying gut microbiome treatments for conditions such as ulcerative colitis, diabetes and irritable bowel syndrome. However, these treatments are not established cures for such conditions. FMT and related products must be used under medical supervision.




